GAMMA Investing LLC Acquires 101,407 Shares of Perrigo Company plc (NYSE:PRGO)

GAMMA Investing LLC boosted its holdings in shares of Perrigo Company plc (NYSE:PRGO - Free Report) by 5,281.6% in the first quarter, according to its most recent filing with the SEC. The firm owned 103,327 shares of the company's stock after acquiring an additional 101,407 shares during the period. GAMMA Investing LLC owned 0.08% of Perrigo worth $2,897,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its holdings in Perrigo by 6,828.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,845,539 shares of the company's stock worth $201,710,000 after acquiring an additional 7,732,309 shares during the period. Dimensional Fund Advisors LP grew its holdings in Perrigo by 0.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 6,989,530 shares of the company's stock worth $179,698,000 after acquiring an additional 27,835 shares during the period. Deprince Race & Zollo Inc. grew its holdings in Perrigo by 1.1% during the 4th quarter. Deprince Race & Zollo Inc. now owns 4,557,844 shares of the company's stock worth $117,182,000 after acquiring an additional 50,728 shares during the period. Cooke & Bieler LP grew its holdings in Perrigo by 4.1% during the 4th quarter. Cooke & Bieler LP now owns 3,573,651 shares of the company's stock worth $91,879,000 after acquiring an additional 139,650 shares during the period. Finally, Ion Asset Management Ltd. grew its holdings in Perrigo by 50.1% during the 4th quarter. Ion Asset Management Ltd. now owns 2,820,000 shares of the company's stock worth $72,502,000 after acquiring an additional 941,667 shares during the period. Institutional investors and hedge funds own 95.91% of the company's stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Perrigo from a "hold" rating to a "buy" rating in a report on Saturday, May 24th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $33.00.

Perrigo Trading Down 2.2%

Shares of NYSE PRGO traded down $0.59 during midday trading on Friday, reaching $26.66. 1,302,094 shares of the stock were exchanged, compared to its average volume of 1,480,626. The business has a 50-day simple moving average of $26.02 and a two-hundred day simple moving average of $26.11. The company has a market capitalization of $3.67 billion, a price-to-earnings ratio of -22.79 and a beta of 0.46. Perrigo Company plc has a 12 month low of $23.14 and a 12 month high of $30.93. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.56 and a quick ratio of 1.77.

Perrigo (NYSE:PRGO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.56 by $0.04. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.09 billion. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The business's quarterly revenue was down 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.29 earnings per share. As a group, equities research analysts expect that Perrigo Company plc will post 2.56 EPS for the current year.

Perrigo Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 17th. Investors of record on Friday, May 30th will be paid a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a yield of 4.35%. The ex-dividend date is Friday, May 30th. Perrigo's payout ratio is presently -88.55%.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.